The outlook of companies tied to flagship drugs like Viagra presents a challenging investment scenario . While the initial surge of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the patent expiration in key regions has introduced substantial volatility. Investors are now grappling with the consequences of rival